A Phase 2 interventional study of GTx-024 in Stress Urinary Incontinence, sponsored by GTx. Completed at 3 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by GTx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.
Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 144th largest by enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2016, is one of 12 in phase 2, and was the 76th registered.
653 studies on the registry are indexed under Urinary Incontinence, Stress; 121 are open to participants now.
Browse Urinary Incontinence, Stress studies →27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, China and 6 more countries
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18–50 · Women only
University of Rochester · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 74 Urinary Incontinence, Stress studies recruiting now, 42 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 23 · Phase 4 15
First in 2001; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 68 across 508 interventional studies indexed under Urinary Incontinence, Stress.
Median enrollment 98 across the 163 interventional studies, 98 across the 26 observational. Of the 129 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 189 have an industry lead sponsor. The 10 most frequent:
GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.
GTx has 4 studies filed under Urinary Incontinence, Stress — fewer than ten, so there is no comparison to draw.
9 of the studies in Urinary Incontinence, Stress with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06968741UroMems SASA Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS) | 2026-12 |
| NCT06111209Brigham and Women's HospitalThe Anabolic Effect of Testosterone on Pelvic Floor Muscles | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
| NCT06706362Ohio State UniversityAssessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study) | 2027-04-15 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 189 studies in Urinary Incontinence, Stress with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
Drug: GTx-024
GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
Also known as: enobosarm
The Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary
To describe the effect of 12 weeks of treatment of GTx-024 on the number of stress incontinence episodes/day as assessed by patient completion of the 3 day voiding diary
Time frame: 12 weeks
Stress Urinary Incontinence as Assessed by 24 Hour Pad Weight Test. Mean Percent Change in Pad Weight
To describe the effect of 12 weeks of treatment of GTx-024 on SUI as assessed by 24 hour pad weight test. Mean percent reduction in pad weight
Time frame: 12 weeks
Number of Participants With Adverse Events
To describe the safety profile of GTx-024 3 mg PO daily in subjects with stress urinary incontinence.
Time frame: 12 weeks
| Milestone | GTx-024 3 mg |
|---|---|
| Started | 19 |
| Completed | 18 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
To describe the effect of 12 weeks of treatment of GTx-024 on the number of stress incontinence episodes/day as assessed by patient completion of the 3 day voiding diary
| percent reduction | GTx-024 3 mg |
|---|---|
| The Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary | 81 (50 to 100) |
To describe the effect of 12 weeks of treatment of GTx-024 on SUI as assessed by 24 hour pad weight test. Mean percent reduction in pad weight
| percent | GTx-024 3 mg |
|---|---|
| Stress Urinary Incontinence as Assessed by 24 Hour Pad Weight Test. Mean Percent Change in Pad Weight | 71 (27 to 126) |
To describe the safety profile of GTx-024 3 mg PO daily in subjects with stress urinary incontinence.
| Participants | GTx-024 3 mg |
|---|---|
| Number of Participants With Adverse Events | 9 |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GTx-024 3 mg | 0/19 (0%) | 0/19 (0%) | 9/19 (47.4%) |
| Event | GTx-024 3 mg |
|---|---|
| headacheGeneral disorders | 1/19 |
| nauseaGastrointestinal disorders | 1/19 |
| muscle sorenessMusculoskeletal and connective tissue disorders | 1/19 |
| arthritisMusculoskeletal and connective tissue disorders | 1/19 |
| fatigueGeneral disorders | 1/19 |
| hot flashEndocrine disorders | 1/19 |
| insomniaGeneral disorders | 1/19 |
| urinary frequencyRenal and urinary disorders | 1/19 |
| acneSkin and subcutaneous tissue disorders | 1/19 |
| tooth abscessInfections and infestations | 1/19 |
| Age, Continuous(years) | GTx-024 3 mg |
|---|---|
| Mean | 61.4 (45 to 80) |
| Sex: Female, Male(Participants) | GTx-024 3 mg |
|---|---|
| Female | 19 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | GTx-024 3 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | GTx-024 3 mg |
|---|---|
| United States | 19 |
| Baseline mean number of stress leaks per day(number of leaks per day) | GTx-024 3 mg |
|---|---|
| Mean | 5.17 (3.33 to 10.33) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2016 to primary completion in Jun 2018, 29 months.
Results were first posted in Feb 2021, 2 years 8 months after primary completion.
Of 15 phase 2 interventional studies under Urinary Incontinence, Stress, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 29 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ostarine
Urinary Incontinence, Stress →
GTx